Beijing Yimiao Shenzhou Pharmaceutical Technology

Developer of AVV cell therapy for the treatment of cancer. Beijing Yimiao Shenzhou Pharmaceutical Technology is a developer of AVV cell therapy for the treatment of cancer. It offers treatment for malignant tumors by the application of CART-T technology and gene cell drugs. It also develops a gene engineering vector technology platform for the delivery of lentiviral vectors for the preparation of CAR-T cell products. Its products include IM19, IM21, and IM23 which are in the clinical stage. The company operates in the Life Sciences > Genomics, Life Sciences > Immunotherapy sector. Founded in 2015 and headquartered in Haidian, China and has raised $42.8 million in Series D funding. Key investors include China Life Insurance, GF Securities, AAMA Chamber of Commerce, SDIC Venture Capital Management, Longmenfund, Shuimushenan, Shougang Fund, Sherpa Venture Capital.